顶部联系方式

Time of issue:2018-03-12 00:00:00

Have Any Questions?  Mabspace BiosciencesInfo@mabspacebio.com 迈博斯生物0512-86861701

搜索
迈博斯生物

语言切换

Time of issue:2019-11-21 00:00:00
这是描述信息

NEWS

>>
>>
Judge Rules in Favor of Amgen on PCSK9

Judge Rules in Favor of Amgen on PCSK9

  • Categories:Industrial News
  • Author:
  • Origin:
  • Time of issue:2019-11-28 14:11
  • Views:

(Summary description)A United States District Court judge in Delaware has granted Amgen's request for a permanent injunction prohibiting Sanofi/Regeneron from manufacturing, using, selling, or offering their monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9)...

Judge Rules in Favor of Amgen on PCSK9

(Summary description)A United States District Court judge in Delaware has granted Amgen's request for a permanent injunction prohibiting Sanofi/Regeneron from manufacturing, using, selling, or offering their monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9)...

  • Categories:Industrial News
  • Author:
  • Origin:
  • Time of issue:2019-11-28 14:11
  • Views:
Information

A United States District Court judge in Delaware has granted Amgen's request for a permanent injunction prohibiting Sanofi/Regeneron from manufacturing, using, selling, or offering their monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9).

According to a statement from Amgen, the injunction will not take effect immediately as the court has delayed its imposition for 30 days to allow Sanofi/Regeneron the opportunity to seek expedited review of the decision.

Officials with Amgen contend Regeneron violated their patents. Both entitites make a PCSK9 inhibitor; Amgen's is evolocumab (Repatha), and Sanofi/Regeneron's is alirocumab (Praluent). Repatha binds to PCSK9 and inhibits circulating PCSK9 from binding to the low-density lipoprotein (LDL) receptor (LDLR).

Even though Regeneron's Praluent was the first drug of this kind to get US FDA approval, the court ruled that Amgen has the rights to sell, market, and manufacture its PCSK9 inhibitor and that Sanofi/Regeneron does not.

"Protecting intellectual property is essential to our industry as it reinforces the incentives for the large and risky investments we make in innovation to bring forward new medicines to treat serious diseases," Robert A. Bradway, chairman and chief executive officer at Amgen said in a prepared statement. Bradway continued, "Heart disease is the biggest health care challenge for society today and Repatha aims to help address this challenge by providing a profound reduction in LDL-cholesterol."

"We will continue to vigorously defend our case through the appeal process as we believe the facts and controlling law support our position," Joseph LaRosa, Senior Vice President, General Counsel and Secretary, Regeneron said in a prepared statement.

Scan the QR code to read on your phone

页脚关于我们

Time of issue:2019-11-23 00:00:00

页脚管道

Time of issue:2019-11-23 00:00:00

页脚新闻

Time of issue:2019-11-23 00:00:00

页脚人力资源

Time of issue:2019-11-23 00:00:00

页脚联系方式

Time of issue:2019-11-23 00:00:00

页脚版权

Time of issue:2019-11-23 00:00:00

Copyright © 2019 Mabspace Biosciences All rights reserved

页脚备案

Time of issue:2019-11-23 00:00:00